Loading…
Immunovant, Inc. is projected to rise to $46.17 by 2027, a +38% move from its current price of $33.41. IMVT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $32.39 | $33.40 | $34.45 | -0.02% |
| May 30 | $31.98 | $33.40 | $34.88 | -0.04% |
| May 31 | $31.66 | $33.39 | $35.22 | -0.06% |
| Jun 1 | $31.40 | $33.39 | $35.50 | -0.07% |
| Jun 2 | $31.16 | $33.38 | $35.75 | -0.09% |
| Jun 3 | $30.96 | $33.37 | $35.98 | -0.11% |
| Jun 4 | $30.76 | $33.37 | $36.19 | -0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.76 | $33.37 | $36.19 | -0.13% |
| Week 2 | $29.71 | $33.32 | $37.38 | -0.26% |
| Week 3 | $28.91 | $33.28 | $38.31 | -0.38% |
| Week 4 | $28.25 | $33.24 | $39.10 | -0.51% |
| Week 5 | $27.68 | $33.20 | $39.81 | -0.64% |
| Week 6 | $27.17 | $33.15 | $40.45 | -0.77% |
| Week 7 | $26.71 | $33.11 | $41.05 | -0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immunovant, Inc. is a clinical-stage immunology company focused on targeted therapies for autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal Fc receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immunovant, Inc. (IMVT) is a healthcare stock currently priced at $34.15 with a market capitalization of $7.01B, and it is ranked 1106 by market cap. This places it among mid-sized healthcare names in the market.
The forecast outlook suggests a rising price trajectory over the coming years. The 2026 average is $34.15, with higher levels projected in subsequent years, including a 2030 average of $61.41 and a 2050 average of $282.10. The path is described as bullish in most years, with the 2040 and 2050 figures showing substantial upside (ROI reaching 302.2% by 2040 and 726.1% by 2050).
A major floor 32.7% below — a decisive break under it would weaken the trend.
The nearest floor, 21.3% below — buyers have tended to step in here.
The nearest ceiling, 6.4% above — a clean break opens room to run.
A major ceiling 22.8% above — clearing it would confirm fresh momentum.
Key IMVT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMVT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $34.22 | Sell | $33.02 | Buy |
| MA 10 | $30.96 | Buy | $31.71 | Buy |
| MA 20 | $29.45 | Buy | $30.21 | Buy |
| MA 50 | $27.28 | Buy | $28.29 | Buy |
| MA 100 | $26.77 | Buy | $26.70 | Buy |
| MA 200 | $23.32 | Buy | $24.69 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 63.53 | Neutral |
| Stoch RSI (14) | 70.00 | Neutral |
| CCI (20) | 110.77 | Buy |
| Williams %R (14) | -23.19 | Info |
| MACD (12,26,9) | 0.56 | Buy |
| ROC (12) | 15.45 | Buy |
| Bollinger %B (20,2) | 0.84 | Neutral |
| Stochastic %K (14) | 76.81 | Neutral |
| TRIX (15) | 0.57 | Buy |
| Awesome (5,34) | 5.56 | Buy |
| Ultimate (7,14,28) | 68.56 | Neutral |
| Momentum (10) | 4.76 | Buy |
| Aroon Osc (25) | 4.00 | Buy |
| Hull MA (9) | 35.66 | Sell |
| ADX (14) | 19.57 | Neutral |
| ATR (14) | 1.09 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70 and near-term momentum supported by bullish sentiment.
The moving averages show SMA50 at $26.93 and SMA200 at $23.14, indicating the price is trading above longer-term average levels. Support is at $25.12 and resistance at $35.56, framing the near-term upside potential.
The 30-day price range spans from a low of $27.56 to a high of $42.31, highlighting the recent volatility within an upward-biased channel. Annualized volatility sits at 60%, underscoring meaningful price fluctuations over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.98 | $33.41 | $48.63 | 0% | Neutral | |
| $36.18 | $46.17 | $62.69 | +38% | Bullish | |
| $39.58 | $52.11 | $73.58 | +56% | Bullish | |
| $41.72 | $56.37 | $82.12 | +69% | Bullish | |
| $43.63 | $60.33 | $90.22 | +81% | Bullish | |
| $41.88 | $59.15 | $90.51 | +77% | Bullish | |
| $45.87 | $66.09 | $103.23 | +98% | Bullish | |
| $55.72 | $81.79 | $130.15 | +145% | Bullish | |
| $60.88 | $90.96 | $147.24 | +172% | Bullish | |
| $67.01 | $101.85 | $167.52 | +205% | Bullish | |
| $80.81 | $132.82 | $233.49 | +298% | Bullish | |
| $145.71 | $274.68 | $531.80 | +722% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $22.98 | $33.41 | $39.35 | +0.00% |
| June 2026 | $28.07 | $33.06 | $39.92 | -1.06% |
| July 2026 | $27.64 | $32.86 | $40.28 | -0.61% |
| August 2026 | $28.88 | $34.59 | $42.89 | +5.27% |
| September 2026 | $29.73 | $35.83 | $44.86 | +3.60% |
| October 2026 | $29.35 | $35.57 | $44.91 | -0.72% |
| November 2026 | $29.77 | $36.26 | $46.11 | +1.92% |
| December 2026 | $31.03 | $37.97 | $48.63 | +4.72% |
Click any year to see its month-by-month IMVT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, IMVT is projected to trade between $22.98 and $48.63, averaging $33.41 — a potential gain of 0% from today's $33.41. A consolidation phase looks the most probable path here.
Immunovant, Inc.'s 2027 outlook centres on $46.17, within a $36.18 to $62.69 range. That is up +38% on the projected 2026 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2028, IMVT could reach as high as $73.58, with a base case around $52.11 and support toward $39.58 — roughly +56% from $33.41. Buyers look set to stay in control over this stretch.
Expect IMVT to range from $41.72 to $82.12 through 2029. The $56.37 average target implies a +69% move from current prices. That is up +8% on the projected 2028 average. Momentum favours further upside here.
The IMVT price prediction for 2030 points to an average of $60.33 (low $43.63, high $90.22) — a potential gain of +81% on today's $33.41. Buyers look set to stay in control over this stretch.
In 2031, IMVT is projected to trade between $41.88 and $90.51, averaging $59.15 — a potential gain of +77% from today's $33.41. That is -2% versus the projected 2030 average. Momentum favours further upside here.
Immunovant, Inc.'s 2032 outlook centres on $66.09, within a $45.87 to $103.23 range. That is up +12% on the projected 2031 average. That marks a +98% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, IMVT could reach as high as $130.15, with a base case around $81.79 and support toward $55.72 — roughly +145% from $33.41. Momentum favours further upside here.
Expect IMVT to range from $60.88 to $147.24 through 2034. The $90.96 average target implies a +172% move from current prices. That is up +11% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The IMVT price prediction for 2035 points to an average of $101.85 (low $67.01, high $167.52) — a potential gain of +205% on today's $33.41. Momentum favours further upside here.
In 2040, IMVT is projected to trade between $80.81 and $233.49, averaging $132.82 — a potential gain of +298% from today's $33.41. That is up +30% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Immunovant, Inc.'s 2050 outlook centres on $274.68, within a $145.71 to $531.80 range. That is up +107% on the projected 2040 average. That marks a +722% change versus current levels. Momentum favours further upside here.
Investing $1,000 in IMVT today (≈ 29.931158 IMVT) could be worth
$8,221.45
+$7,221.45 (+722%) by 2050 · US Dollar
Based on the average projected IMVT price of $274.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMVTwould be worth at today's price.
$1,000 invested in IMVT on May 27, 2025 (≈ 69.979006 IMVT) would be worth
$2,338
+$1,338 (+133.8%) today · 2.34× · US Dollar
Based on a IMVT entry price of $14.29 vs. today's $33.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.56 | $939.54 | -6.0% |
| 1 month ago | $28.62 | $1,167.37 | +16.7% |
| 3 months ago | $27.41 | $1,218.9 | +21.9% |
| 6 months ago | $24.15 | $1,383.44 | +38.3% |
| 1 year ago | $14.29 | $2,338 | +133.8% |
| All time (5.0y) ago | $9.4 | $3,554.26 | +255.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMVT forecast.
Our base-case forecast reaches $67.00 around 2033.
Implied market cap at $67.00: $13.76B
The multi-year forecast paints a strong upside trajectory. In 2027 the average is projected at $47.30 with a 38.5% ROI and bullish sentiment, followed by 2028 at $54.09 (58.4%), 2029 at $58.13 (70.2%), and 2030 at $61.41 (79.8%). The bullish path continues into 2031 ($60.65, 77.6%), 2032 ($67.73, 98.3%), and 2033 ($84.00, 146%).
Further ahead, 2034 carries an average of $94.13 (175.6%), and 2035 at $104.98 (207.4%), with continued bullish momentum into 2040 ($137.36, 302.2%) and 2050 ($282.10, 726.1%). These figures imply sustained upside even as the price forecasts rise toward higher long-term targets, though they come with inherent uncertainty and market risk. The forecast also indicates broad bullish sentiment across the long horizon, with implied volatility contributing to the potential for outsized moves.
Tap a question to reveal the answer.
Avg $61.41, Min $43.87, Max $93.07; ROI 79.8%; Sentiment bullish.
The forecast shows bullish sentiment from 2027 onward, with averages rising from $47.30 (2027) to $282.10 (2050) and ROI climbing to 726.1% by 2050. The year 2026 is neutral with an avg of $34.15.
Yes. The 2033 max is $135.83 and the 2035 avg is $104.98, with 2034 max $154.94 and 2040 max $246.32, indicating a path above $100 within the forecast horizon.
Current price is $34.15 and market cap is $7.01B.
Low $27.56, High $42.31.
Immunovant, Inc. Community Discussion
0Share your Immunovant, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.